Trial Profile
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Cetrorelix (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 18 Jan 2011 Additional trial locations (Bulgaria, Germany) identified as reported by ClinicalTrials.gov.
- 29 Dec 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Aug 2009 Status changed from completed to active, no longer recruiting.